A Study of Siliphos in Adults With Non-alcoholic Steatohepatitis (NASH)

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the dietary supplement Siliphos, which comes from milk thistle, to determine whether it is safe and well-tolerated in adults who have non-alcoholic steatohepatitis (NASH). An additional aim of this study is to determine whether Siliphos may be beneficial in treatment of NASH as indicated by improvement in liver enzymes (ALT and AST). The study hypothesis is that Siliphos will be safe and well-tolerated in people with NASH and will result in a decrease in the liver enzymes ALT and AST.

Clinical Trial Description

Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver conditions characterized by fat accumulation in the liver. Non-alcoholic steatohepatitis (NASH) is one form of NAFLD that may progress to cirrhosis in some people. Currently, there are no medications that are approved for the treatment of NASH. Milk thistle is sold over-the-counter as a dietary supplement. Milk thistle has been used for hundreds of years as a supplement to support liver function, and is commonly taken by people with a variety of liver conditions. Milk thistle may help to reduce inflammation and fibrosis (scar tissue) in the liver, so it may be beneficial in the treatment of NASH. As NAFLD is very common in the population, there are probably many people with NAFLD taking milk thistle supplements. However, there are no published studies of milk thistle in NAFLD. Therefore, this study is designed to provide preliminary evidence of the safety, tolerability, and efficacy of milk thistle in people with NASH. Comparison: The milk thistle supplement (called Siliphos) will be compared to a placebo (sugar pill) in this study. ;

Study Design

Related Conditions & MeSH terms

Fatty Liver
Non-alcoholic Fatty Liver Disease

Clinical Trial Details

NCT number	NCT00443079
Study type	Interventional
Source	University of California, San Diego
Contact
Status	Completed
Phase	Phase 2
Start date	March 2007
Completion date	December 2009

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05979779` - Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis	Phase 2
Recruiting	`NCT06051669` - Comparison of iLivTouch and FibroScan for the Assessment of Liver Fibrosis and Steatosis in Adult Patients in the US
Not yet recruiting	`NCT05984745` - Effect of CoQ10 on the Outcome of MAFLD Patients	Phase 2
Completed	`NCT02565446` - Transforming Non-Invasive Liver Disease Detection by MRE: The Hepatogram	N/A
Not yet recruiting	`NCT01694342` - Telomere Parameters in Patients With Nonalcoholic Fatty Liver	N/A
Completed	`NCT01464801` - Resveratrol in Patients With Non-alcoholic Fatty Liver Disease	N/A
Completed	`NCT01992809` - Omega 3 Supplementation in Fatty Liver	Phase 3
Completed	`NCT00063635` - Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)	Phase 3
Completed	`NCT00244569` - Development of a Breath Test for Monitoring Patients With Liver Disease	Phase 3
Recruiting	`NCT03972319` - Omega-3 Supplementation for LIver VolumE Reduction Study (OLIVER) Study	Early Phase 1
Completed	`NCT03141008` - Evaluation of Liver and Cardiometabolic Health Benefits on Low Carbohydrate Ketogenic Diet
Completed	`NCT03614039` - Effect of Probiotic and Smectite Gel on NAFLD	N/A
Recruiting	`NCT05125757` - Lifestyle Modification in Psoriatic Patients With Fatty Liver	N/A
Recruiting	`NCT05370053` - The Availability of the Enhanced Liver Fibrosis (ELF) Test Affects the Rate of Diagnosis of Nonalcoholic Steatohepatitis (NASH) With Fibrosis in Patients Referred to Hepatology	N/A
Recruiting	`NCT04371042` - PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies
Completed	`NCT04004273` - Diabetes, Exercise and Liver Fat (DELIVER)	N/A
Completed	`NCT02520609` - Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
Recruiting	`NCT02265276` - A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease	Phase 3
Completed	`NCT02347007` - Impact of Almond Supplementation on Body Composition in Overweight/Obese Minority Adults	N/A
Completed	`NCT01934777` - Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis	Phase 3